New investigational drugs with single-agent activity in multiple myeloma

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

(2016) P. G. Richardson et al.   BLOOD

Monoclonal Antibodies for the Treatment of Myeloma

(2016) Sagar Lonial   CANCER JOURNAL

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

(2016) Niels W. C. J. van de Donk et al.   IMMUNOLOGICAL REVIEWS

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

(2015) J. J. Shah et al.   BLOOD

Is the open mouth mightier than the needle?

(2015) P. Martin   BLOOD

Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses

(2015) J. M. Moreau et al.   BLOOD

Phase 1, multicenter, open-label, dose-escalation, combination study (NCT02103335) of pomalidomide (POM), marizomib (MRZ, NPI-0052), and dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma (MM); study NPI-0052-107 preliminary results

(2015) A. Spencer et al.   Clinical Lymphoma Myeloma & Leukemia

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors

(2015) Patricia M. LoRusso et al.   INVESTIGATIONAL NEW DRUGS

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

(2015) S Lonial et al.   LEUKEMIA

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

(2015) S M Matulis et al.   LEUKEMIA

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpretation of cytogenetic results in multiple myeloma for clinical practice

(2015) A M Rajan et al.   Blood Cancer Journal

Targeting the Pim kinases in multiple myeloma

(2015) N A Keane et al.   Blood Cancer Journal

Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management

(2014) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

(2014) P. D. Garcia et al.   CLINICAL CANCER RESEARCH

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains

(2013) Mathew P. Martin et al.   ACS Chemical Biology

"A fortuitous combination of circumstances"

(2013) S. Lonial   BLOOD

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation

(2013) J. Lu et al.   BLOOD

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism

(2013) T. K. Nguyen et al.   MOLECULAR CANCER THERAPEUTICS

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

(2012) S. Kumar et al.   BLOOD

Sequence and structure relationships within von Willebrand factor

(2012) Y.-F. Zhou et al.   BLOOD

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520

(2010) B. J. Tunquist et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications

(2008) V. Sarli et al.   CLINICAL CANCER RESEARCH